Pell Bio Med Technology Co Ltd
TWSE:6949
Pell Bio Med Technology Co Ltd
TWSE:6949
Price:
579
TWD
1.94%
Market Closed
Market Cap:
NT$37.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Pell Bio Med Technology Co Ltd
TWSE:6949
|
TW |
|
Race Oncology Ltd
ASX:RAC
|
AU |
|
United Bancshares Inc
OTC:UBOH
|
US |
|
Burford Capital Ltd
NYSE:BUR
|
GG |
|
A
|
Agilent Technologies Inc
XBER:AG8
|
US |
|
W
|
Whirlpool Corp
DUS:WHR
|
US |
|
W
|
Woojin I&S Co Ltd
KRX:010400
|
KR |
|
Franklin BSP Capital Corp
OTC:FRBP
|
US |
|
T
|
Tata Steel Ltd
LSE:TTST
|
IN |
|
Harena Resources PLC
OTC:CRMNF
|
UK |
Balance Sheet
Balance Sheet Decomposition
Pell Bio Med Technology Co Ltd
Pell Bio Med Technology Co Ltd
Balance Sheet Decomposition is not available for
Pell Bio Med Technology Co Ltd
Pell Bio Med Technology Co Ltd
Balance Sheet
Pell Bio Med Technology Co Ltd
Pell Bio Med Technology Co Ltd
Currency: TWD
| Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Cash Equivalents |
116
|
172
|
168
|
427
|
|
| Cash |
96
|
125
|
133
|
427
|
|
| Cash Equivalents |
20
|
48
|
34
|
0
|
|
| Short-Term Investments |
0
|
536
|
938
|
709
|
|
| Total Receivables |
11
|
6
|
8
|
4
|
|
| Accounts Receivables |
4
|
6
|
8
|
4
|
|
| Other Receivables |
6
|
0
|
0
|
1
|
|
| Inventory |
4
|
5
|
4
|
6
|
|
| Other Current Assets |
1
|
6
|
10
|
11
|
|
| Total Current Assets |
132
|
725
|
1 127
|
1 158
|
|
| PP&E Net |
250
|
299
|
267
|
502
|
|
| PP&E Gross |
250
|
299
|
267
|
502
|
|
| Accumulated Depreciation |
50
|
69
|
83
|
102
|
|
| Intangible Assets |
1
|
3
|
2
|
2
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
11
|
17
|
22
|
83
|
|
| Total Assets |
394
N/A
|
1 044
+165%
|
1 418
+36%
|
1 745
+23%
|
|
| Liabilities | |||||
| Accounts Payable |
9
|
6
|
7
|
4
|
|
| Accrued Liabilities |
19
|
15
|
40
|
64
|
|
| Short-Term Debt |
0
|
5
|
0
|
200
|
|
| Current Portion of Long-Term Debt |
11
|
25
|
25
|
28
|
|
| Other Current Liabilities |
6
|
7
|
17
|
25
|
|
| Total Current Liabilities |
44
|
57
|
89
|
321
|
|
| Long-Term Debt |
125
|
173
|
147
|
137
|
|
| Minority Interest |
0
|
14
|
11
|
106
|
|
| Total Liabilities |
169
N/A
|
243
+44%
|
248
+2%
|
565
+128%
|
|
| Equity | |||||
| Common Stock |
334
|
444
|
539
|
578
|
|
| Retained Earnings |
186
|
417
|
818
|
1 202
|
|
| Additional Paid In Capital |
77
|
774
|
1 449
|
1 804
|
|
| Treasury Stock |
0
|
0
|
1
|
1
|
|
| Total Equity |
225
N/A
|
801
+256%
|
1 170
+46%
|
1 180
+1%
|
|
| Total Liabilities & Equity |
394
N/A
|
1 044
+165%
|
1 418
+36%
|
1 745
+23%
|
|
| Shares Outstanding | |||||
| Common Shares Outstanding |
46
|
46
|
54
|
58
|
|
Switch to:
Switch to:
See Also
Discover More
